Type 2 diabetes
Conditions
Interventions
None listed
Sponsors
minamiosakahospital, Internal medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age: 20 years old or older and under 80 years old. 2. Gender: No matter. 3. Those who have been diagnosed with type 2 diabetes more than 1 year before the start of the study and have been treated with dulaglutide for more than 3 months before the screening.4. Glycoalbumin (GA) 20% or more. 5. Those who have passed more than 6 months since the introduction of hemodialysis. 6. A person who has received sufficient explanation for participating in this research, and who has obtained the consent of the document by his / her free will after sufficient understanding. 7. Those who can go to the outpatient clinic according to the research implementation schedule
Exclusion criteria
Exclusion criteria: 1. Patients with a history of severe ketosis, diabetic coma or precoma within 6 weeks of the start of the study. 2. Patients who develop severe hypoglycemia (diabetic coma or precoma, convulsions, etc. that require the assistance of a third party) within 6 weeks of the start of the study. 3. Patients with a history of chronic or idiopathic acute pancreatitis. 4. Patients with a history of acute coronary or cerebrovascular events within 90 days, NYHA class IV heart failure. 5. Patients with proliferative retinopathy (However, patients who have undergone photocoagulation and have stable symptoms can be included). 6. Patients with a history of surgery for serious gastrointestinal disorders. 7. Pregnant or potentially pregnant women and lactating patients. 8. Patients with severe infections, before and after surgery, and with serious trauma. 9. Patients receiving systemic corticosteroids. 10. Patients with severe liver dysfunction (high AST or ALT of 100 U / L or more). 11. Patients with a history of allergies to the drugs to be used in the study. 12. Patients with malignant tumor or history of malignant tumor. 13. Other patients judged by the investigator to be inappropriate as subjects.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage of CGM blood glucose 70-180 mg / dl (normal range) time for 3 days each on HD and non-HD days for each treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| (1) Percentage of CGM blood glucose level <70 mg / dl (hypoglycemic range) and blood glucose level <54 mg / dl (severe hypoglycemic range) for 3 days each on HD and non-HD days in each treatment method Percentage, blood glucose level 180 mg / dl or higher (hypoglycemic range) time percentage, average blood glucose level, SD value, CV value, M value, MAGE,(2) Changes in HbA1c and glycoalbumin levels, (3) BMI at the end of HD on weekends, (4) BW with one non-dialysis day and BW with two non-dialysis days, (5) Weekend Changes in hANP value after dialysis. | — |
Countries
Japan
Contacts
Public Contactshoko miyamoto
minamiosakahospital Internal medicine
Outcome results
None listed